DCLK1-IN-1 |
| カタログ番号GC39486 |
DCLK1-IN-1 は、キナーゼ 1 (DCLK1 キナーゼ) ドメインのような doublecortin の選択的な経口バイオアベイラビリティー in vivo 互換性化学プローブです。 DCLK1-IN-1 は、DCLK1 および DCLK2 キナーゼを阻害します (IC50: DCLK1 =9.5/57.2 nM および DCLK2 =31/103 nM 結合およびキナーゼ アッセイでそれぞれ)。 DCLK1-IN-1 は低毒性を示し、DCLK1 生物学を調査し、DCLK1+ 膵管腺癌 (PDAC) のような癌におけるその役割を確立することができます。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2222635-15-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
DCLK1-IN-1 is a selective, oral bioavailability in vivo-compatible chemical probe of the doublecortin like kinase 1 (DCLK1 kinase) domain. DCLK1-IN-1 inhibits DCLK1 and DCLK2 kinases (IC50: DCLK1=9.5/57.2 nM and DCLK2=31/103 nM in binding and kinase assay, respectively). DCLK1-IN-1 shows low toxicity, and can investigate DCLK1 biology and establish its role in cancer, like DCLK1+ pancreatic ductal adenocarcinoma (PDAC)[1].
[1]. Ferguson FM, et al. Discovery of a selective inhibitor of doublecortin like kinase 1. Nat Chem Biol. 2020 Apr 6.
Average Rating: 5 (Based on Reviews and 14 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *